help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 57, No. 6 1140-1144
doi:10.1210/jcem-57-6-1140
Copyright © 1983 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SANKE, T.
Right arrow Articles by MIYAMURA, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SANKE, T.
Right arrow Articles by MIYAMURA, K.

Glucagon Binding Autoantibodies in a Patient with Hyperthyroidism Treated with Methimazole*

TOKIO SANKE, MICHI KONDO, YOSHIHIRO MORIYAMA, KISHIO NANJO, KAZUHIRO IWO and KEI MIYAMURA

Endocrinological Department of Internal Medicine, Wakayama Medical School Wakayama, Japan

Address correspondence and requests for reprints to: Tokio Sanke, M.D., Endocrinological Department of Internal Medicine, Wakayama Medical School, 7-bancho, Wakayama 640, Japan.

A 47-yr-old woman who had previously received methimazole (MMI) treatment for hyperthyroidism was found to have glucagon binding autoantibodies in plasma. She had never received glucagon. The binding substances were detected in plasma at the time of a glucagon RIA. [125I] Glucagon binding was inhibited only by porcine glucagon and porcine glicentin, and dissociated at acid pH. The substances proved to be glucagon binding antibodies (immunoglobulin G, L-chain K-type), as determined by ammonium sulfate and radioprecipitation. There were no clinical manifestations related the presence of these autoantibodies. In a survey of 91 patients with thyroid disease, 3 patients whose plasma bound [125I]glucagon were identified among 41 with hyperthyroidism who were receiving MMI treatment. Such binding was not found in plasma from untreated hyperthyroid patients, those receiving propylthiouracil or those with chronic thyroiditis. These findings suggest that the development of glucagon antibodies in hyperthyroidism may be associated with MMI treatment.

* This work was presented at the 7th Asia and Oceania Congress of Endocrinology, Tokyo, Japan, 1982.

Received January 31, 1983.




This article has been cited by other articles:


Home page
ANN INTERN MEDHome page
S. SAKATA, S. NAKAMURA, and K. MIURA
Autoantibodies Against Thyroid Hormones or lodothyronine: Implications in Diagnosis, Thyroid Function, Treatment, and Pathogenesis
Ann Intern Med, October 1, 1985; 103(4): 579 - 589.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1983 by The Endocrine Society